NCT06079190

Efficacy and Safety of GSK4527226 [AL101] in Participants With Early Alzheimer's Disease

Name: Clinical Trial NCT06079190
Creator: GlaxoSmithKline
Keywords: Alzheimer's Disease, GSK4527226, Phase 2, drug, clinical trial, Argentina,Australia,Canada,Finland,France,Germany,Italy,Netherlands,Norway,South Korea,Spain,Sweden,

A Phase 2, Parallel Group, Randomized, Double- Blind, Placebo-Controlled, 3-Arm, Multicenter Treatment Study to Evaluate the Efficacy and Safety of GSK4527226 [AL101] Intravenous Infusion Compared With Placebo in Patients With Early Alzheimer's Disease

GlaxoSmithKline·Phase 2·ClinicalTrials.gov·drugNot yet recruiting

View on ClinicalTrials.gov →

Study focus

Disease/Condition: Alzheimer's Disease
Drug/Device/Intervention: GSK4527226
Study type: Interventional
Intervention type: drug

Sponsor & location

Primary sponsor: GlaxoSmithKline
Location: San Diego,DeLand,Maitland,Miami,Orlando,Stuart,The Villages,Wellington,Decatur,Elk Grove Village,Wichita,Chesterfield,Toms River,New York,New York,Staten Island,Matthews,North Canton,Oklahoma City,Por, Argentina,Australia,Canada,Finland,France,Germany,Italy,Netherlands,Norway,South Korea,Spain,Sweden,

Timeline & enrollment

Phase: Phase 2
Start date: Oct 11, 2023
End date: May 16, 2029
Enrollment: 282 participants

Primary outcome

Change from Baseline in Clinical Dementia Rating - Sum of Boxes (CDR-SB) Score for Dose 1 vs Placebo Across Weeks 52, 64 and 76

Summary

The aim of this study is to assess the efficacy and safety of GSK4527226 in participants with early Alzheimer's Disease (AD) (including mild cognitive impairment [MCI] and mild dementia due to AD) of 2 dose levels of GSK4527226 compared to placebo.

ICD-10 classifications

Alzheimer diseaseAlzheimer disease, unspecifiedOther Alzheimer diseaseDementia in Alzheimer diseaseDementia in Alzheimer disease, unspecified

Data source

Registry: ClinicalTrials.gov
Trial ID: NCT06079190
Type: Non-Device Trial

About this record

Access comprehensive clinical trial information for NCT06079190 through Pure Global AI's free database. This Phase 2 trial is sponsored by GlaxoSmithKline and is currently Not yet recruiting. The study focuses on Alzheimer's Disease. Target enrollment is 282 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.